Can I read Oral propionyl‐l‐carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease on EtoBox?

Oral propionyl‐l‐carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease by G. Cavallini; G. Biagiotti; A. Koverech; G. Vitali is a Medicine article available to read on EtoBox.

What is Oral propionyl‐l‐carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease about?

**Objective** To ascertain whether oral propionyl‐l‐carnitine combined with intraplaque verapamil is a useful therapy for advanced or resistant Peyronie's disease. **Patients and methods** The combined drugs were assessed in two studies. In the first, 60 patients with advanced Peyronie's disease, diagnosed using accepted definitions, were randomized in two subgroups treated with verapamil intraplaque infiltration (10 mg weekly for 10 weeks) plus a 3‐month administration of propionyl‐l‐carnitine (2 g/day), or verapamil infiltration plus oral tamoxifen (40 mg/day) for 3 months. In the second study, 15 patients with resistant Peyronie's disease (progression despite previous therapy) received verapamil plus propionyl‐l‐carnitine. The differences between subgroups or between the variables before and after therapy were compared using analysis of variance or the chi‐squared test. **Results** In the first study, the reduction in pain was the same in both subgroups. Propionyl‐l‐carnitine plus verapamil significantly reduced penile curvature, plaque size, cavernosal artery end‐diastolic velocity, the need for surgery and disease progression, and increased the International Index of Erectile

Who reads Oral propionyl‐l‐carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease?

Author

G. Cavallini; G. Biagiotti; A. Koverech; G. Vitali

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 1464-4096)

Published

2002

Language

EN

Field

Medicine (Health Sciences)